<DOC>
	<DOCNO>NCT01339910</DOCNO>
	<brief_summary>The study design Phase III , multicenter trial compare outcome allogeneic hematopoietic stem cell transplantation ( HCT ) acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) patient receive myeloablative conditioning ( MAC ) versus reduce intensity conditioning ( RIC ) regimens .</brief_summary>
	<brief_title>Reduced Intensity Regimen v Myeloablative Regimen Myeloid Leukemia Myelodysplastic Syndrome ( BMT CTN 0901 )</brief_title>
	<detailed_description>Patients randomize RIC receive one two regimen type : combination fludarabine ( 120-180 mg/m^2 ) busulfan ( less equal 8 mg/kg IV equivalent ) ( Flu/Bu ) fludarabine ( 120-180 mg/m^2 ) melphalan ( le 150 mg/m^2 ) ( Flu/Mel ) . Patient randomize MAC receive one three regimen : busulfan ( 16 mg/kg oral 12.8 mg/kg IV equivalent ) cyclophosphamide ( 120 mg/kg ) ( Bu/Cy ) ; , busulfan ( 16 mg/kg PO 12.8 mg/kg IV ) fludarabine ( 120-180 mg/m^2 ) ( Bu/Flu ) ; , cyclophosphamide ( 120 mg/kg ) total body irradiation ( great 1200-1420cGy ) ( CyTBI ) . A total 356 patient ( 178 arm ) accrue study period four year . Patients follow 18 month transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Age equal less 65 year old equal great 18 year old . Patients diagnosis MDS AML few 5 % myeloblast bone marrow leukemic myeloblast peripheral blood morphologic analysis perform within 30 day start condition regimen enrollment . For patient receive treatment MDS AML prior transplantation : ) Interval start recent cycle conventional cytotoxic chemotherapy enrollment must least 30 day ; b ) Interval complete treatment hypomethylating agent noncytotoxic chemotherapy enrollment must least 10 day . Patients must relate unrelated bone marrow peripheral blood donor human leukocyte antigen ( HLA ) match 7 8 8 HLAA , B , C DRB1 high resolution use DNAbased typing . HCTSpecific Comorbidity Index Score ( HCTCI ) less equal 4 . Organ function : ) Cardiac function : Ejection fraction great equal 40 % ; b ) Hepatic function : total bilirubin less equal 2 time upper limit normal alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less equal 3 time upper limit normal . ; c ) Pulmonary function : Diffusing capacity lung carbon monoxide ( DLCO ) great equal 40 % forced expiratory volume one second ( FEV1 ) great equal 50 % ( correct hemoglobin ) . Creatinine clearance great equal 50mL/min base CockcroftGault formula . Signed informed consent . Prior allograft prior autograft . Symptomatic coronary artery disease . Leukemia involvement central nervous system ( CNS ) within 4 week enrollment patient history prior CNS leukemia involvement ( i.e. , leukemic blast previously detect cerebral spinal fluid ) . Karnofsky Performance Score less 70 . Patients receive supplemental oxygen . Planned use donor lymphocyte infusion ( DLI ) therapy . Patients uncontrolled bacterial , viral fungal infection ( undergo appropriate treatment progression clinical symptom ) . Patients seropositive human immunodeficiency virus ( HIV ) . Patients prior malignancy , except resect basal cell carcinoma treat cervical carcinoma situ . Cancer treat curative intent great 5 year previously . Cancer treat curative intent le 5 year previously allow unless approve Protocol Officer one Protocol Chairs . Females pregnant breastfeeding . Fertile men woman unwilling use contraceptive technique 12 month follow treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>